Locations:

Tag: alzheimer’s disease (AD)

January 19, 2021/Geriatrics

CYCLE-AD Trial: High-Intensity Exercise to Stave Off Alzheimer’s Disease

New NIH-funded study tests home-based intervention in high-risk group

20-NEU-1971409_welcome-to-Nevada_650x450

September 18, 2020/Geriatrics

Getting Serious About Curbing Rural Disparities in Dementia Care and Research

NIA grant helps establish Nevada exploratory Alzheimer’s Disease Research Center

August 13, 2020/Geriatrics

New Insights Into Inflammation-Related Pathways Predicting Cognitive Decline in Alzheimer’s

Longitudinal study implicates a specific pathway in mild cognitive impairment stage

July 8, 2020/Basic & Translational Science

Studies of an Alpha-1 Adrenergic Agonist for Alzheimer’s Advance With New NIA Grant

$2 million will enable preclinical dose and efficacy testing of “compound 3”

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

September 7, 2018/Basic & Translational Science

Funding Award Enables First Study to Examine Cognitive Effects of an Alpha-1 Agonist

Cleveland Clinic-developed “compound 3” begins testing in preclinical Alzheimer’s model

18-NEU-5506-Phase-3-Alzheimers-Trials-650×450

August 27, 2018/Geriatrics

Analysis of Alzheimer’s Drug Pipeline Reveals Slow Progress, a Few Bright Spots

Third annual report shows shift toward prevention studies, disease-modifying therapies

February 20, 2018/Basic & Translational Science

Reversal of Alzheimer’s in Mouse Model Boosts BACE1 Inhibitors’ Prospects in Humans

Most substantial reversal of amyloid deposition in an animal study to date

15-ETH-2567-PreclinicalAlzheimers-650×450-CQD

April 4, 2016/Bioethics/Research

Preclinical Alzheimer’s: Study Examines Consequences of Documenting Biomarker Test Results

Probing how insurers, employers will use information

BackPage 3 of 3Next